• linkedin
  • Increase Font
  • Sharebar

    Metastatic PCa: Studies point to new standard of care

    New findings from two large-scale, international studies support the use of upfront treatment with abiraterone acetate (ZYTIGA) in men with metastatic prostate cancer.

    The phase III international LATITUDE trial met its co-primary endpoints, demonstrating that adding abiraterone acetate plus prednisone (AA+P) to androgen deprivation therapy (ADT) significantly improved overall survival (OS) and significantly prolonged radiographic progression-free (rPFS) survival in men newly diagnosed with high-risk, metastatic castration-sensitive prostate cancer (mCRPC).

    The second trial, STAMPEDE, found that abiraterone added to standard initial treatment reduced the risk of death by 37% over 3 years compared with standard of care alone in men with locally advanced or metastatic prostate cancer.

    Both studies’ results were reported at the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine (June 4, 2017) and (June 3, 2017).

    LATITUDE randomized 1,199 men 1:1 to ADT plus AA, 1,000 mg/day, and prednisone, 5 mg/day, or ADT plus placebos for both medications. Lead author Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, presented findings from a first interim analysis that was planned to be done when about 50% of expected death events had occurred. It was conducted at a median follow-up of 30.4 months after 406 deaths.

    Next: Compared with the control group, men treated with AA+P in addition to ADT had a 38% reduction in the risk of death (p<.001)


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available